Company Encyclopedia
View More
name
RenovoRx
RNXT.US
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
1.912 T
RNXT.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking304/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-146.61%E
    • Profit Margin-1196.66%E
    • Gross Margin80.08%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-21.19%D
    • Total Assets YoY11.71%B
    • Net Assets YoY14.24%A
  • Cash ScoreD
    • Cash Flow Margin-8.36%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreB
    • Gearing Ratio27.91%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares

    Shaun Bagai, CEO of RenovoRx Inc., has reported acquiring common shares of the company. This information was originally published by RenovoRx Inc. via the EDGAR system of the U.S. Securities and Exchange Commission. The news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    RNXT
    +3.33%
    Reuters·
    US
    RNXT
    +3.33%

    Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength

    Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday. Kura Oncology, Inc. (KURA) led with a 7.42% rise, likely due to positive data from its KOMET-007 trial. SOPHiA GENETICS SA (SOPH) gained 5.21%, reflecting interest in its collaboration with Complete Genomics. Other gainers included Elutia Inc. (ELUT), RenovoRx, Inc. (RNXT), Kodiak Sciences Inc. (KOD), Day One Biopharmaceuticals, Inc. (DAWN), and Quantum BioPharma Ltd. (QNTM).

    rttnews·
    US
    ELUT
    +8.03%
    US
    RNXT
    +3.33%
    US
    KOD
    -1.44%
    rttnews·
    US
    ELUT
    +8.03%
    US
    RNXT
    +3.33%
    US
    KOD
    -1.44%

    CEO Bagai Buys 5,000 ($4.3K) Of RenovoRx Inc [RNXT]

    Bagai Shaun Chief Executive Officer of RenovoRx Inc [RNXT] filed a Form 4 on December 19, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/17/25TransactionPurchaseShares5,000Price$0.85Value$4,262Ending Holdings: 335,040 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    RNXT
    +3.33%
    Reuters·
    US
    RNXT
    +3.33%

    RenovoRx (NASDAQ:RNXT) Insider Ramtin Agah Purchases 12,000 Shares

    RenovoRx insider Ramtin Agah purchased 12,000 shares at $0.85 each, totaling $10,200, increasing his ownership by 1.57% to 778,460 shares. The transaction was disclosed in an SEC filing. RenovoRx's stock performance shows a trading price of $0.89, with a market cap of $32.55 million. Analysts have mixed ratings, with a consensus "Hold" and a target price of $7.75. RenovoRx is a clinical-stage biopharmaceutical company focusing on cancer therapies.

    Market Beat·
    US
    RNXT
    +3.33%
    Market Beat·
    US
    RNXT
    +3.33%

    Chmn Agah Buys 12,000 ($10.2K) Of RenovoRx Inc [RNXT]

    Agah Ramtin Chairman of the Board of RenovoRx Inc [RNXT] filed a Form 4 on December 17, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/16/25TransactionPurchaseShares12,000Price$0.85Value$10,200Ending Holdings: 778,460 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    RNXT
    +3.33%
    Reuters·
    US
    RNXT
    +3.33%
    © 2025 Longbridge｜Disclaimer